As a dermatologist at Harvard Medical School, Jennifer has seen how immunotherapies, such as immune checkpoint inhibitors, can treat melanoma—a type of aggressive skin cancer—effectively in some patients but not others. Her BroadIgnite project seeks to understand this variability in patient response using recently developed spatial sequencing approaches in mouse models and patient samples. She aims to uncover mechanisms underlying resistance to checkpoint inhibitors in melanoma; identify ways to promote patient response to treatments; and test novel immunotherapy strategies.